Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Presentation with an isolated proximal humeral fracture after a low-energy trauma (e.g. falling from a standing position) and:~* indication for open reduction and internal fixation with a proximal humeral locking plate (PHILOS®, Synthes, Switzerland) after low energy trauma~  * displacement of more than 1 cm between fragments and/or~ * angulation of 45° or more between the fragments and/or~ * dislocation of the greater tuberosity of 5 mm or more and/or~ * patient specific factors like high functional demand etc~* age \> 50 years~* postmenopausal status (i.e. 12 continuous month without menstruation)~* informed consent in surgery and study participation~Exclusion Criteria:~* Psychiatric disorder severely impairing co-operation (dementia mini mental Status (MMS) \<24, schizophrenia, major depression)~* Pathological fractures caused by other conditions~* Fracture-related nerve injury~* Malignancies under current treatment (i.e. chemotherapy, radiotherapy etc.)~* BMI \<20 kg/m2~* Known hypersensitivity to one of the graft components~* Participation in a clinical trial within 3 month before enrolment

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cellularized composite graft augmentation (Type: EXPERIMENTAL): lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800® cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;
- Control acellular composite graft augmentation (Type: ACTIVE_COMPARATOR): open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute.

Based on this trial design, predict the completion outcome and termination type (if applicable).